Chair of Microbiology

    Development of vaccines

    We have developed an innovative vaccination strategy against SARS-CoV-2 based on the well-tolerated, oral live Salmonella enterica Serovar Typhi vaccine Ty21a that harbours one of our novel antigen delivery plasmids of the JMU-SalVac-100 series.

    The JMU-Salmonella Vaccine (JMU-SalVac) platform technology offers high flexibility and plenty of possible combinations for fine tuning of the desired immune response against various antigens of interest, like for example antigens of SARS-CoV-2.


    The primary objective of our project is to translate one or more promising recombinant SARS-CoV-2 vaccine candidates into the clinics.


    • Construction of various SARS-CoV-2 vaccine candidates and their characterization
    • Selection-process of lead candidate(s)
    • Preclinical evaluation of safety and efficacy
    • Establishing a GMP process suitable for production of bacterial vaccines
    • GMP production of one or more SARS-CoV-2 vaccine strains based on recombinant Salmonella Typhi Ty21a
    • Clinical evaluation of safety and efficacy